<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02063360</url>
  </required_header>
  <id_info>
    <org_study_id>206281</org_study_id>
    <secondary_id>AI438-020</secondary_id>
    <nct_id>NCT02063360</nct_id>
  </id_info>
  <brief_title>DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)</brief_title>
  <official_title>Open-Label, Single-Sequence Study to Evaluate the Pharmacokinetic Interaction of BMS-663068 With Darunavir/Ritonavir and/or Etravirine in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if there is an interaction in healthy subjects
      taking BMS-663068 with Darunavir/Ritonavir and/or Etravirine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Brief title: drug-drug interaction (DDI)

      Primary Purpose: Other : Phase 1 Clinical Pharmacology drug interaction study in healthy
      subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1, 2014</start_date>
  <completion_date type="Actual">May 13, 2014</completion_date>
  <primary_completion_date type="Actual">May 1, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-626529</measure>
    <time_frame>20 timepoints up to day 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve in 1 dosing interval (AUC(TAU)) of BMS-626529</measure>
    <time_frame>20 timepoints up to day 26</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) for BMS-626529, DRV, RTV, and ETR</measure>
    <time_frame>Up to day 26 (20 timepoints for BMS-626529, 24 timepoints for DRV, RTV and ETR)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at 12 hours (C12) for BMS-626529, DRV, RTV, and ETR</measure>
    <time_frame>Up to day 26 (20 timepoints for BMS-626529, 24 timepoints for DRV, RTV and ETR)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (Ctrough) for BMS-626529, DRV, RTV, and ETR</measure>
    <time_frame>Up to day 26 (20 timepoints for BMS-626529, 24 timepoints for DRV, RTV and ETR)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for DRV, RTV, and ETR</measure>
    <time_frame>24 timepoints up to 26 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(TAU) for DRV, RTV, and ETR</measure>
    <time_frame>24 timepoints up to 26 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability endpoints include incidence of adverse event (AEs), serious adverse event (SAEs), AEs leading to discontinuation, deaths, marked laboratory abnormalities, and abnormalities in vital signs, physical examination, and 12-lead ECGs</measure>
    <time_frame>Up to day 27</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Cohort 1: BMS-663068+DRV/RTV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg orally orally twice daily on days 7-16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: BMS-663068+ETR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet ETR 200mg orally orally twice daily on days 7-16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: BMS-663068+DRV/RTV+ETR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg and ETR 200mg orally orally twice daily on days 7-16</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-663068</intervention_name>
    <description>BMS-663068</description>
    <arm_group_label>Cohort 2: BMS-663068+ETR</arm_group_label>
    <arm_group_label>Cohort 3: BMS-663068+DRV/RTV+ETR</arm_group_label>
    <arm_group_label>Cohort 1: BMS-663068+DRV/RTV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir (DRV)</intervention_name>
    <description>Darunavir (DRV)</description>
    <arm_group_label>Cohort 3: BMS-663068+DRV/RTV+ETR</arm_group_label>
    <arm_group_label>Cohort 1: BMS-663068+DRV/RTV</arm_group_label>
    <other_name>Prezista</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir (RTV)</intervention_name>
    <description>Ritonavir (RTV)</description>
    <arm_group_label>Cohort 3: BMS-663068+DRV/RTV+ETR</arm_group_label>
    <arm_group_label>Cohort 1: BMS-663068+DRV/RTV</arm_group_label>
    <other_name>Norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etravirine (ETR)</intervention_name>
    <description>Etravirine (ETR)</description>
    <arm_group_label>Cohort 2: BMS-663068+ETR</arm_group_label>
    <arm_group_label>Cohort 3: BMS-663068+DRV/RTV+ETR</arm_group_label>
    <other_name>Intelence</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects with no clinically significant deviation from normal in medical
             history, physical examination findings, 12-lead ECG measurements, and clinical
             laboratory tests

          -  Women of childbearing potential (WOCBP) allowed. Must be practicing highly effective
             methods of contraception

        Exclusion Criteria:

          -  Any significant acute or chronic medical condition

          -  Unable to tolerate oral medications

          -  Inability to be venipunctured and/or tolerate venous access

          -  Current or recent (within 3 months of dosing) gastrointestinal disease

          -  Abnormal liver function test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2014</study_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Etravirine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

